
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2016

AETHLON MEDICAL, INC.
(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of incorporation)

001-37487
(Commission File Number)

13-3632859
(IRS Employer
Identification Number)

9635 Granite Ridge Drive, Suite 100
San Diego, California
(Address of principal executive offices)

92123
(Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by the registrant from time to time with the Securities and Exchange Commission (collectively, the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management. When used in the Filings the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to the registrant or the registrant's management identify forward-looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, the registrant's operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although the registrant believes that the expectations reflected in the forward-looking statements are reasonable, the registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

ITEM 7.01 REGULATION FD DISCLOSURE.

Today, June 3, 2016, Mr. James Joyce, Chief Executive Officer of Aethlon Medical, Inc. (the "Company"), presented at the 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum. A link to the presentation may be accessed on the Company's website under the investor relations section of the website. The website address is www.aethlonmedical.com. No portion of the website shall be deemed to be incorporated into this Current Report on Form 8-K.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. (d) EXHIBITS

EXHIBIT NO.	DESCRIPTION
-------------	-------------

99.1	Presentation materials – 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum – June 3, 2016
------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

Dated: June 3, 2016

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Presentation materials – 2nd Annual Sachs Associates Immuno-oncology: BD&L and Investment Forum – June 3, 2016

Aethlon Medical, Inc.

Nasdaq: AEMD

SACHS IMMUNO-ONCOLOGY
BD&L INVESTMENT FORUM
JUNE 3, 2016

Jim Joyce
Chairman, CEO



FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon ADAPT™ and ELLSA™ platform technologies, the Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com



IMMUNOTHERAPEUTIC TECHNOLOGIES TO COMBAT INFECTIOUS DISEASE & CANCER



TUMOR-DERIVED EXOSOMES

A Basis for Therapeutic and Diagnostic Partnering





Initiated tumor-derived
exosome research in 2006

*Considered cellular debris with
no biological function*




2016

*Tumor-derived exosomes are significant
therapeutic and diagnostic targets*



Tumor-Derived Exosomes



Tumor-Derived Exosomes

A Significant Unmet Medical Need in Cancer

- The seeds of cancer metastasis
 - The mystery of the Soil & Seed Theory of 1889
- Tumor-derived exosomes promote:
 - Tumorigenesis
 - Cancer progression
 - Angiogenesis
 - Immune-evasion
 - Resistance to radiation and chemotherapeutic drugs
- Exosome load correlates with stage of cancer



The Aethlon Hemopurifier®



Broad-spectrum elimination of circulating viruses, bacterial toxins and tumor-derived exosomes





DEPLOYED WITHIN THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT MACHINES



The Aethlon Hemopurifier®



FDA approved IDE study currently being conducted



The Hemopurifier® Mechanism of Action

- Rapid separation of disease targets from the circulatory blood path
- Capture of disease targets through adherence to immune-evasion structure
 - Lectin-affinity attachment to high-mannose structure that cloaks exosome and pathogen targets from immune surveillance
- Normal blood components are returned to the circulatory system



Previous Human Treatment Experiences



HIV/AIDS Patient



Average viral load reductions > 50%
observed during 4hr treatments



Hepatitis C Virus (HCV)



HCV Treatment Summary

- Demonstrated successful use in interferon-based cure strategy
- Up to 300 billion HCV copies captured during single six-hour treatments



Ebola Virus





Hemopurifier® therapy
administration to a
comatose Ebola patient
with multiple-organ failure





Dr. Stefan Büttner
Holding Hemopurifier®
After Ebola Treatment



Ebola Treatment Data

Presented By Dr. Helmut Geiger

American Society of Nephrology Annual Meeting

- 6.5 hour Hemopurifier® therapy administration
- Pre-treatment viral load: 400,000 copies/ml
- Post-treatment viral load: 1,000 copies/ml
- 242 million of Ebola viruses captured
- Patient recovered and returned home





“Top 25 Best Inventions”

“11 Most Remarkable Advances in Healthcare”



In Vitro Hemopurifier® Validations

- Viruses
 - Hepatitis C, HIV, Ebola, H1N1 Swine Flu, H5N1 Bird Flu, 1918 Spanish Flu (reconstructed), Monkey Pox, West Nile Virus, Chikungunya and Dengue
- Viral Toxins
 - Ebola glycoprotein (gp), HIV gp120, HIV NEF-exosomes
- Bacterial Toxins
 - Lipopolysaccharide (LPS) and Lipoteichoic acid (LTA)
- **Tumor-derived Exosomes**
 - **Breast, Metastatic Melanoma and Ovarian**




Expansive Exosome IP Portfolio

Issued & Pending Patents Teach

- Therapeutic elimination of exosomes
- Isolation of exosomes from bodily fluids
 - platform to diagnose and monitor cancer
- Exosome harvesting
 - exosomal delivery of biologic & chemotherapeutic agents



Partnering/Collaboration Initiatives



Partnering/Collaboration Initiatives


- **Therapeutic elimination of exosomes**
 - Preclinical Hemopurifier-drug study validations
 - Confirm combination Hemopurifier-drug synergies
 - Demonstrate non-affinity binding of drug agent
 - Expand potential therapeutic indications
 - Clinical program initiatives
 - Full-circle immuno-oncology treatment regimens
 - Chemotherapy optimization regimens



Partnering/Collaboration Initiatives

- Therapeutic elimination of exosomes
- Isolation of exosomes from bodily fluids
 - platform to diagnose and monitor cancer
- Exosome harvesting
 - Exosomal delivery of biologic & chemotherapeutic agents





ELLSA™ (Enzyme-linked lectin-specific assay)
Proprietary broad-spectrum exosome isolation platform



Partnering/Collaboration Initiatives

- **Isolation of exosomes from bodily fluids**
 - ELLSA co-development partnerships
 - ELLSA isolation + antibody step to diagnose and monitor specific disease indications
 - Urine based proof-of-principal established in HIV



Partnering/Collaboration Initiatives


- Therapeutic elimination of exosomes
- Isolation of exosomes from bodily fluids
 - platform to diagnose and monitor cancer
- **Exosome harvesting**
 - **Exosomal delivery of biologic & chemotherapeutic agents**
 - **Contact management to initiate discussions**



IMMUNOTHERAPEUTIC TECHNOLOGIES TO COMBAT INFECTIOUS DISEASE & CANCER



Tumor-Derived Exosomes A Basis for Therapeutic & Diagnostic Partnering



CONTACT:

Aethlon Medical, Inc

9635 Granite Ridge Drive
Suite 100
San Diego, California 92123

Jim Joyce
Chairman & CEO
jj@aethlonmedical.com
858.459.7800 x301

